ArticleCVIR endovascular2026
Use of the Wrapsody™ Cell-Impermeable Endoprosthesis for the treatment of pelvic congestion syndrome due to nutcracker syndrome.
Article in CVIR endovascular, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endovascular stenting is a preferred treatment approach for the management of pelvic congestion syndrome (PCS) secondary to nutcracker syndrome. However, there is no consensus on which stenting device is advantageous for patients. In this report, we summarize off-label use of the Wrapsody™ Cell-Impermeable Endoprosthesis (CIE) for this condition. A 30-year-old woman presented with chronic left flank and lower abdominal pain, progressively worsening since childbirth. Imaging demonstrated compression of the left renal vein between the aorta and superior mesenteric artery with reflux into the ovarian vein. Endovascular treatment was performed using a 14 × 40 mm CIE. The procedure was technically successful and symptomatic resolution was achieved without complications. Follow-up over 2 years confirmed persistent device patency and absence of venous congestion. This case highlights that the CIE, a device originally designed for restoration of hemodialysis access, is an effective endovascular option for managing PCS due to nutcracker syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.